Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
41 results about "Chemosensitizer" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
A chemosensitizer is a drug that makes tumor cells more sensitive to the effects of chemotherapy.
Therapeutic combinations comprising poly (ADP-ribose) polymerases inhibitor
This invention generally relates to use of 8-fluoro-2{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one represented by formula 1 as a chemosensitizer that enhances the efficacy of cytotoxic drugs or radiotherapy. This invention provides pharmaceutical combinations of 8-fluoro-2{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one, or a pharmaceutically acceptable salt thereof and at least one additional therapeutic agent, kits containing such combinations and methods of using such combinations to treat subjects suffering from diseases such as cancer.
Owner:AGOURON PHARMA INC +1
Selective PARP-1 targeting for designing chemo/radio sensitizing agents
InactiveUS7072771B2Affect activityMicrobiological testing/measurementBiological testingBiological activationDrug target
Poly(ADP-ribose) polymerase-1 (PARP-1) is a central signaling enzyme in a cell nucleus. PARP-1 is a target for the development of radio and chemo sensitizing agents in cancer treatment as well as providing protection from stroke. An SH3 domain and an SH3 ligand domain have now been discovered on the PARP-1 protein. These domains are involved in PARP-1 activation. This discovery makes possible the use of bioinformatics tools for the design of new drugs and strategies for drug target selection, specifically targeting the PARP-1 enzyme.
Owner:UNIV OF KENTUCKY RES FOUND
Adriamycin nano drug delivery system as well as preparation method and application thereof
ActiveCN103976950AUniform particle sizeLarge particle sizeOrganic active ingredientsOrganic non-active ingredientsLipid formationOrganic solvent
The invention discloses an adriamycin nano drug delivery system as well as a preparation method and application thereof. The drug delivery system comprises the following components in percentage by weight: 0.02%-1.5% of active ingredient containing adriamycin, 1%-20% of solid lipid, 0.1%-20% of liquid lipid, 0.5%-20% of emulsifier and 0.1%-5% of isoosmotic adjusting agent, wherein the solid lipid and the liquid lipid form nanoparticles to cover the active ingredient containing the adriamycin. The preparation method comprises the following steps: (1), uniformly dispersing the active ingredient containing the adriamycin, the solid lipid, the liquid lipid and fat-soluble emulsifier in an organic solvent, evaporating the organic solvent to obtain an oil phase; (2), uniformly dispersing other emulsifiers and the isoosmotic adjusting agent in water to obtain a water phase; (3), adding the water phase into the oil phase for emulsifying drop by drop; (4), homogenizing under high pressure; (5), cooling and degerming. The adriamycin nano drug delivery system disclosed by the invention can be used for realizing co-transporting of the adriamycin and a chemosensitizer, so that the killability of the adriamycin on liver cancer cells is strengthened.
Owner:HUAZHONG UNIV OF SCI & TECH +1
High-activity anti-caner new medicament formalardeemin for inhibiting multi-drug resistance of tumor cells
The invention relates to indole alkaloid formalardeemin shown in a chemical structural formula ((-)-5-N-formalardeemin), pharmaceutically acceptable salts of the same, and application of the indole alkaloid formalardeemin serving as an anti-tumor medicament in curing malignant tumors of human beings. The indole alkaloid formalardeemin serving as an anti-tumor medicament can not only inhibit the growth of malignant tumors directly, but also can be used as a chemosensitizer when used together with other anti-tumor medicaments such as doxorubicine, vincristine and the like to achieve the effect of effectively killing tumor cells by reversing the multi-drug resistance of the tumor cells. More significantly, compared with the indole alkaloid formalardeemin serving as a tumor cell growth inhibitor directly, the indole alkaloid formalardeemin serving as the chemosensitizer has a better effect, so the indole alkaloid formalardeemin has important clinical application prospect.
Owner:成都常春藤生物科技有限公司
Kit for postoperative and prognosis evaluation of liver cancer and liver cancer chemosensitizer
The invention discloses a kit for postoperative and prognosis evaluation of liver cancer, and relates to the field of biological medicine. The kit comprises an agent for quantitatively detecting an expression level of micro RNA (Ribonucleic Acid) molecules miR-653 in to-be-detected liver tissues; a nucleotide sequence of the miR-653 is as shown in Seq ID No.1. Active ingredients of a liver cancer chemosensitizer comprise the mutually prepared micro RNA molecules miR-653 and a precursor of the micro RNA molecules miR-653, or an overexpression vector capable of effectively expressing the micro RNA molecules miR-653 and / or the precursor of the miR-653; the precursor of the micro RNA molecules miR-653 is encoded by a DNA (Deoxyribose Nucleic Acid) sequence as shown in Seq ID No.2. Experimental data verify the effectiveness of the kit disclosed by the invention in the aspect of postoperative and prognosis evaluation of liver cancer and verifies that the sensitizer based on the miR-653 can effectively reinforce the sensitivity of liver cancer cells for a chemotherapy drug sorafenib.
Owner:SOUTH CENTRAL UNIVERSITY FOR NATIONALITIES
IAP nucleobase oligomers and oligomeric complexes and uses thereof
InactiveUS20050148535A1Easy to produceSugar derivativesGenetic material ingredientsOligomerApoptosis
The present invention provides nucleobase oligomers and oligomer complexes that inhibit expression of an IAP polypeptide, and methods for using them to induce apoptosis in a cell. The nucleobase oligomers and oligomer complexes of the present invention may also be used to form pharmaceutical compositions. The invention also features methods for enhancing apoptosis in a cell by administering a nucleobase oligomer or oligomer complex of the invention in combination with a chemotherapeutic or chemosensitizing agent.
Owner:AEGERA THERAPEUTICS INC
Method for determination and quantification of radiation or genotoxin exposure
InactiveUS20050255502A1Increased focus formationIncreased formationMicrobiological testing/measurementPreparing sample for investigationToxinChemosensitizing agent
The present invention discloses methods for detecting exposure of a living subject to genotoxic agents, testing sensitivity to a genotoxic agent, and determining DNA damage caused by exposure to an agent, comprising detecting the presence of FANCD2-containing foci from a sample collected from said subject. The presence of concentrated foci is indicative of DNA damage, and the degree of foci formation is correlated with degree of exposure. Diagnostic reagents contain a ligand that binds to human FANCD2 associated with a detectable label. Kits for detecting DNA damage in a biological sample contain such diagnostic reagents and signal detection components. The invention further discloses methods for identifying agents which modulate the ability of FANCD2-containing foci to form. Among other things, such agents are potentially useful chemosensitizing agents or may confer protection against damage caused by genotoxic agents.
Owner:DANA FARBER CANCER INST INC
Epothilone resistant cell lines
Epothilone resistant cells lines are disclosed. The invention also discloses methods for identifying substances which are cytotoxic to epothilone resistant cells or which are chemosensitizers or analogs of epothilone. The invention further discloses methods for identifying epothilone resistant cells and for inhibiting the growth of epothilone resistant cells in vitro and in vivo. The invention also discloses antibodies specific for epothilone resistant cells. Also disclosed is a method to identify microtubule stabilizing agents using the epothilone resistant cell lines disclosed.
Owner:ATADJA PETER WISDOM +3
Preparation method and application of polycarbonate drug-loaded nano chemosensitizer based on nitric oxide
PendingCN113679845AStrong drug loading capacitySolve absorptionPowder deliveryOrganic active ingredientsTumor targetTumor targeting
The invention discloses a preparation method and application of a polycarbonate drug-loaded nano chemosensitizer based on nitric oxide. The sensitizer is prepared by self-assembling a polycarbonate block copolymer containing a nitric oxide donor and a small molecule chemotherapeutic drug. The polycarbonate drug-loaded nano chemosensitizer based on nitric oxide has the advantages of good water solubility, small toxic and side effects, good stability in a normal physiological environment and the like, and effectively solves the problems of poor water solubility, large toxic and side effects and the like of indissolvable chemotherapeutic drugs such as adriamycin, mitoxantrone and the like in clinical use. The polycarbonate drug-loaded nano chemosensitizer based on nitric oxide also has the features that the drug-loading capacity is high, the tumor targeting property is remarkable, the tumor microenvironment can be regulated and controlled, the ideal chemotherapy sensitization effect is achieved, and tumor recurrence is reduced.
Owner:CHINA PHARM UNIV
Targeting human thymidylate kinase induces DNA repair toxicity in malignant tumor cells
The present invention relates to novel TMPK inhibitor and their methods of use. In particular, it relates to novel TMPK inhibitor of Formula (I) and therapeutics that decrease the cellular dTTP level to suppress the growth and inhibit DNA repair in tumor cells and acts as a novel chemosensitizer, which are useful in methods for treating or preventing cancers.
Owner:NATIONAL YANG MING UNIVERSITY +1
Anti-cancer composition and method for using the same
InactiveUS20080038376A1Increase rmsImprove the environmentBiocideInorganic phosphorous active ingredientsAbnormal tissue growthMelanoma
This invention encompasses an expeditious method and compositions that have been found to show selective cytotoxicity against several different cancer cell lines. for treating a wide variety cancer neoplasms that have tumor microenvironments by administering a stand-alone anti-tumor chemotherapeutic composition or administered as an adjunct with chemotherapy and / or radiotherapy with enhanced tumor site affinity that preferentially elevates the pH at the tumor site to suppress and eliminates the acidic tumor microenvironment, administered as chemosensitizing and / or radiosensitizers enhancing the tumor, suppression, remission and inhibit tumor metastisis. The invention encompasses controlling mechanisms of intracellular and extracellular ionic physiology through the administration of alkali salts for pH modulating and for restoring and enhancing ionic physiology. The compositions are useful in effective treatment of cancers, particularly malignant melanomas and squamous cell carcinomas (SCCs), thereby inhibiting angiogenesis, reducing metastatic proliferation, supressing tumor generated induced acidotic pain.
Owner:PHARMAIONX
Methods for screening therapeutically effective agents
InactiveUS6982142B2Good choiceLess manipulationMicrobiological testing/measurementBiological material analysisGlycolipid metabolismGlycolipid
Methods of detecting novel therapeutically active compositions based on their ability to modulate the glycolipid metabolism and overcome multidrug resistance are described. These methods are particularly useful in screening for novel chemotherapeutic agents for the treatment of cancer, as well as chemosensitizers that are capable of enhancing the cytotoxicity of such chemotherapeutic agents. A combination of one or more of these compositions can be used in the treatment of a various cancers.
Owner:JOHN WAYNE CANCER INST
Liposome including elastin-like polypeptide conjugated to moiety containing hydrophobic group, chemosensitizer and anticancer agent and use thereof
InactiveUS20130101666A1BiocideCarbohydrate active ingredientsAnticarcinogenElastin like polypeptides
A liposome including a lipid bilayer, an elastin-like polypeptide (ELP) conjugated to a hydrophobic moiety; a chemosensitizer; and an anticancer agent, a pharmaceutical composition including the same, and a method of delivering a chemosensitizer and an anticancer agent to a target site of a subject by using the liposome.
Owner:SAMSUNG ELECTRONICS CO LTD
Application of cryptotanshinone in preparation of chemosensitizer for Ph+ acute lymphocytic leukemia
ActiveCN109864991AHigh efficiency and low toxicityImprove applicabilityOrganic active ingredientsAntineoplastic agentsAcute lymphocytic leukemiaPre treatment
The invention discloses an application of cryptotanshinone in preparation of a chemosensitizer for acute lymphocytic leukemia, and application of combination of cryptotanshinone and anticancer drugs in preparation of drugs for treating and / or preventing acute lymphocytic leukemia, drug resistance reversal drugs and / or drugs for preventing relapse after pre-treatment. According to research discovery of the present invention, when cryptotanshinone and anticancer drugs are combined for use, cryptotanshinone and anticancer drugs are compounded to greatly increase the sensitivity of leukemia cellsto anticancer drugs, and the proliferation inhibition effect of multiple anticancer drugs on acute lymphocytic leukemia cells is improved in an explosive manner, so that the usage amount of each drugis far lower than that of the current clinical drug, and the explosive synergistic interaction effect is realized. Therefore, cryptotanshinone is used as an effective chemosensitizer for acute lymphocytic leukemia, and has important research significance and wide application prospect in the aspects of treating acute lymphocytic leukemia and solving the problem of drug resistance of acute lymphocytic leukemia.
Owner:SUN YAT SEN UNIV
Novel anticancer-aiding compound, method for preparing the same, anticancer-aiding composition containing the same and method for reducing anticancer drug resistance using the same
ActiveUS20120190724A1Growth inhibitionInhibitory activityBiocideOrganic chemistryCombinatorial chemistryPharmaceutical medicine
The present invention provides a novel xanthone derivative compound or a pharmaceutically acceptable salt thereof. The compound is useful as a chemosensitizer that reduces anticancer drug resistance.
Owner:EWHA UNIV IND COLLABORATION FOUND
Novel application of gossypol
InactiveCN103655526AActivity that inhibits bindingIncreased chemosensitivityAldehyde active ingredientsAntineoplastic agentsAdjuvantDamage repair
The invention relates to the field of medicines, and discloses novel application of gossypol. The gossypol can be used for effectively inhibiting the activity of NF-kappa B, AP-1 and HIF-1 alpha which are induced by reduction-oxidation of APE1 (apurinic / apyrimidinic endonuclease-1) and combined with DNA (deoxyribonucleic acid), and also remarkably inhibiting the DNA damage repairing function of APE1, so that the invention provides the application of gossypol in preparing an APE1 reduction-oxidation inhibitor or a DNA damage repairing function inhibitor of APE1. Furthermore, gossypol can be used for improving the sensitivity of tumor cells to etoposide chemotherapy, and can also reverse drug resistance of the tumor cells to chemotherapeutic medicines caused by high expression of APE1 in the tumor cells, so that the invention also provides application of gossypol in preparing adjuvants or chemosensitizer for treating cancers.
Owner:THE THIRD AFFILIATED HOSPITAL OF THIRD MILITARY MEDICAL UNIV OF PLA
Methods for screening therapeutically effective agents
InactiveUS20020160354A1Good choiceLess manipulationMicrobiological testing/measurementBiological material analysisGlycolipid metabolismPharmaceutical drug
Methods of detecting novel therapeutically active compositions based on their ability to modulate the glycolipid metabolism and overcome multidrug resistance are described. These methods are particularly useful in screening for novel chemotherapeutic agents for the treatment of cancer, as well as chemosensitizers that are capable of enhancing the cytotoxicity of such chemotherapeutic agents. A combination of one or more of these compositions can be used in the treatment of a various cancers.
Owner:JOHN WAYNE CANCER INST
Targeting Human Thymidylate Kinase Induces DNA Repair Toxicity in Malignant Tumor Cells
The present invention relates to novel TMPK inhibitor compositions and their methods of use. In particular, it relates to novel TMPK inhibitor compositions and therapeutics that lead to dUTP-mediated DNA repair in tumor cells and acts as a novel chemosensitizer, which are useful in methods for treating or preventing cancers.
Owner:NATIONAL YANG MING UNIVERSITY +1
Application of solasodine in preparing antitumor drug
InactiveCN104224815APrevent proliferationGood treatment effectOrganic active ingredientsAntineoplastic agentsChemo therapySolasodine
The invention belongs to the field of medicines, relates to application of solasodine in preparing an antitumor drug and particularly relates to application of solasodine in preparing a drug-resistant reversal agent of an antitumor drug. The solasodine is a natural product which has effect of reversing multidrug resistance of tumor cells, and can be used as a reversal agent for multidrug resistance of tumors. The solasodine further has effects of increasing sensitivity of tumor multidrug-resistant cells on the anti-tumor drug and can be used as a chemosensitizer. The invention further provides a method for inhibiting tumor multidrug-resistant cell multiplication by a pharmaceutical composition that combines the anti-tumor drug and solasodine. According to the invention, a small molecule compound solasodine can be used as a novel antitumor drug or an auxiliary ingredient thereof to be developed, and is obvious in tumor inhibiting effect, green and environment-friendly, so that a new way and means is provided for treating and curing tumors.
Owner:FUDAN UNIV
A kind of doxorubicin nanometer drug-carrying system, its preparation method and its application
ActiveCN103976950BImprove proliferative abilityUniform particle sizeOrganic active ingredientsOrganic non-active ingredientsOrganic solventOil phase
The invention discloses an adriamycin nano drug delivery system as well as a preparation method and application thereof. The drug delivery system comprises the following components in percentage by weight: 0.02%-1.5% of active ingredient containing adriamycin, 1%-20% of solid lipid, 0.1%-20% of liquid lipid, 0.5%-20% of emulsifier and 0.1%-5% of isoosmotic adjusting agent, wherein the solid lipid and the liquid lipid form nanoparticles to cover the active ingredient containing the adriamycin. The preparation method comprises the following steps: (1), uniformly dispersing the active ingredient containing the adriamycin, the solid lipid, the liquid lipid and fat-soluble emulsifier in an organic solvent, evaporating the organic solvent to obtain an oil phase; (2), uniformly dispersing other emulsifiers and the isoosmotic adjusting agent in water to obtain a water phase; (3), adding the water phase into the oil phase for emulsifying drop by drop; (4), homogenizing under high pressure; (5), cooling and degerming. The adriamycin nano drug delivery system disclosed by the invention can be used for realizing co-transporting of the adriamycin and a chemosensitizer, so that the killability of the adriamycin on liver cancer cells is strengthened.
Owner:HUAZHONG UNIV OF SCI & TECH +1
Borate chemotherapy sensitizer with symmetrical structure as well as preparation method and application of borate chemotherapy sensitizer
ActiveCN114848657AStimulus responsiveEasy to retouchInorganic active ingredientsBoron compound active ingredientsPharmacometricsDrug release
The invention belongs to the related fields of pharmacology, functional molecules and the like, and particularly relates to a borate chemosensitizer with a symmetrical structure as well as a preparation method and application of the borate chemosensitizer. The chemotherapy sensitizer prepared by the invention has good biocompatibility, stimuli responsiveness and easy modification, can be used for preparing a small-molecule prodrug, and can weaken an intracellular detoxification system while triggering drug release, so that the chemotherapy sensitizer has a good application prospect in the aspect of overcoming chemotherapy drug resistance.
Owner:ANQING NORMAL UNIV
New application of nobiletin and nobiletin composition
PendingCN113712956AReduce outflowAvoid damageOrganic active ingredientsAntipyreticEfficacyPharmacology
The invention belongs to the technical field of medicine preparation, and particularly relates to a new application of nobiletin and a nobiletin composition. The nobiletin is applied to preparation of drugs for reducing P-gp expression in synovial tissues of arthritis. Combined use of nobiletin and methotrexate can reduce cartilage and bone injuries and improve swelling and arthritis injury. On the other hand, nobiletin can reverse P-gp expression in patients with arthritis injury, thereby reducing outflow of the methotrexate and maintaining effect of the methotrexate. The nobiletin and the methotrexate have an obvious synergistic effect. The growth inhibition and apoptosis of RA-FLS / methotrexate cells can be recovered through the joint treatment of the nobiletin and the methotrexate at noncytotoxic concentration of nobiletin. The nobiletin can be used as a potential chemical sensitizer to overcome drug resistance in RA.
Owner:BEIJING UNIV OF CHINESE MEDICINE
Chemotherapy-sensitizing polypeptide aggregate and its preparation method and application
ActiveCN109675015BImprove permeabilityEfficient killingOrganic active ingredientsHeavy metal active ingredientsCancer cellChemotherapeutic drugs
The invention discloses a chemotherapy-sensitizing polypeptide aggregate and its preparation method and application. The polypeptide combination is composed of two polypeptide fragments with different functions, one of which has a target recognition function, and the other contains an assembly unit and has an assembly function. Driving function, the two polypeptides can self-assemble through efficient click reaction to form polypeptide aggregates with chemosensitizing effect. The method disclosed in the present invention can aggregate the polypeptide at the target site through specific design, improve the retention capacity of the polypeptide through the aggregation behavior at the target site, and at the same time, the aggregation of the polypeptide can disturb the cell membrane to promote the uptake of chemotherapy drugs by cancer cells. Through the design of the polypeptide aggregate and the selection of indications, the present invention provides a new idea for the transformation and development of the polypeptide aggregate, and also provides a new treatment method for the chemotherapy of cancer cells, especially drug-resistant cancer cells.
Owner:HARBIN MEDICAL UNIVERSITY
Targeting human thymidylate kinase induces DNA repair toxicity in malignant tumor cells
ActiveUS9662328B2Group 4/14 element organic compoundsSilicon compound active ingredientsThymidylate kinaseTumor cells
The present invention relates to novel TMPK inhibitor and their methods of use. In particular, it relates to novel TMPK inhibitor of Formula (I) and therapeutics that decrease the cellular dTTP level to suppress the growth and inhibit DNA repair in tumor cells and acts as a novel chemosensitizer, which are useful in methods for treating or preventing cancers.
Owner:NATIONAL YANG MING UNIVERSITY +1
Synthesis And Use Of Fluorophore-Tagged Antimalarials
InactiveUS20120100555A1Electrolysis componentsVolume/mass flow measurementLive cell imagingFluorophore
This invention includes a fluorophore-tagged antimalarial represented by the following structural formula (1) or a salt thereof. This invention relates to the synthesis of fluorophore-tagged antimalarials and describes the synthesis of a fluorophore-tagged antimalarial. These fluorophore-tagged antimalarials can be used to image live cells to determine the location of the antimalarial in the cell, identify drug resistance and growth related pathways in Plasmodium isolates, identify new drug targets and chemo-sensitizers to reverse drug resistance.
Owner:NAT UNIV OF SINGAPORE
Use of 2α-hydroxy protopanaxadiol in the preparation of tumor multidrug resistance reversal agent
InactiveCN104208074BPrevent proliferationGood treatment effectOrganic active ingredientsAntineoplastic agentsNatural productProtopanaxadiol
Owner:FUDAN UNIV
Kit for postoperative prognosis assessment of liver cancer and chemotherapy sensitizer for liver cancer
The invention discloses a kit for postoperative and prognosis evaluation of liver cancer, and relates to the field of biological medicine. The kit comprises an agent for quantitatively detecting an expression level of micro RNA (Ribonucleic Acid) molecules miR-653 in to-be-detected liver tissues; a nucleotide sequence of the miR-653 is as shown in Seq ID No.1. Active ingredients of a liver cancer chemosensitizer comprise the mutually prepared micro RNA molecules miR-653 and a precursor of the micro RNA molecules miR-653, or an overexpression vector capable of effectively expressing the micro RNA molecules miR-653 and / or the precursor of the miR-653; the precursor of the micro RNA molecules miR-653 is encoded by a DNA (Deoxyribose Nucleic Acid) sequence as shown in Seq ID No.2. Experimental data verify the effectiveness of the kit disclosed by the invention in the aspect of postoperative and prognosis evaluation of liver cancer and verifies that the sensitizer based on the miR-653 can effectively reinforce the sensitivity of liver cancer cells for a chemotherapy drug sorafenib.
Owner:SOUTH CENTRAL UNIVERSITY FOR NATIONALITIES
Screening probe of medicine for inducing tumor cell epithelial-mesenchymal transition as well as preparation method and application of screening probe
PendingCN114317542AOrganic chemistryFluorescence/phosphorescenceCarboxyl radicalBiomarker (medicine)
The invention belongs to the technical field of medicines, and discloses a screening probe of a medicine for inducing tumor cell epithelial-mesenchymal transition, which is characterized in that the screening probe is formed by modifying the 5'end of an aptamer SYL3C and modifying 6-carboxyl fluorescein at the 3 'end of the aptamer SYL3C. According to the probe disclosed by the invention, by identifying a biomarker epithelial adhesion molecule down-regulated in an epithelial-mesenchymal transition process, an epithelial-mesenchymal transition positive drug is screened according to reduction of a normalized fluorescence intensity signal of cell viability after drug administration. In addition, the chemosensitizer for blocking epithelial-mesenchymal transition and an epithelial-mesenchymal transition inducer TGF-beta are jointly administered, and the chemosensitizer is screened according to the recovery condition of a normalized fluorescence intensity signal of cell viability after the chemosensitizer is administered.
Owner:CHINA PHARM UNIV
Preparation and Application of Brain Tumor Targeting Liposomes Modified by Glucose and Triphenylphosphonium
ActiveCN113230417BPharmaceutical non-active ingredientsAntineoplastic agentsTumor targetingTriphenyl phosphonium
Owner:SICHUAN UNIV
Ubiquitin-specific peptidase 24 inhibitor, medicinal composition including the same and method of delaying or reversing multidrug resistance in cancers using the same
PendingUS20220024887A1Eliminate the problemDelaying and reversing multidrug resistanceOrganic chemistryPeptidasesCancer cellPhenyl group
The present invention relates to a ubiquitin-specific peptidase 24 inhibitor, a medicinal composition including the same and a method of delaying or reversing multidrug resistance in cancers using the same. The USP24 inhibitor, which includes a shUSP24 RNA and / or a carbonyl substituted phenyl compound, can serve as a chemosensitizing agent for inhibiting the drug pump out, cancer sternness and genomic instability of cancer cells, thereby being applied to a medicinal composition and a method for delaying or reversing multidrug resistance in cancers.
Owner:NAT CHENG KUNG UNIV
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com